Grail launched its long-awaited Galleri multi-cancer early detection blood test in the US.
Galleri uses targeted methylation analysis of circulating cell-free DNA to detect a wide range of cancer signals in the blood. It is indicated for patients with an elevated risk of cancer, including adults aged 50 or older, as a complement to existing single-cancer screening tests
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?